Results 221 to 230 of about 867,189 (360)

Melanoma immunotherapy

Oncoscience, 2015
Garg, Abhishek, Dudek-Peric, Aleksandra M., Agostinis, Patrizia   +2 more
openaire   +3 more sources

Intelligent Micro/Nanorobots for Targeted Interventional Therapy: From Bench to Clinic

Advanced Robotics Research, EarlyView.
Zirui Zhang et al. reviewed the application and challenges of mobile nanomachines in interventional therapy. By converting exogenous energy, including chemical, magnetic, optical, and ultrasonic sources, into mechanical forces, micro/nanorobots (MNRs) enable precise actuation at unprecedented scales. Evolving far beyond traditional drug delivery, these
Zirui Zhang, Yu Dong, Yongsheng Du, Rui Gao, Lin Zhang, Fei Tong   +5 more
wiley   +1 more source

Immunotherapy Rechallenge in HCC: A Second Chance for Response? [PDF]

Liver Int
Da Fonseca LG, Guerrero A, Muñoz-Martínez SG.   +2 more
europepmc   +1 more source

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

Advanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin, Saurabh Singh, Soumya Chatterjee, Guang‐Zhi Sui, Yi‐Fu Wang, Ya‐Ting Lu, Yu‐Ling Lee, Kun‐Yuan Lin, Joy Khag, Ta‐Yu Liu, Shao‐Han Chang, Wai‐Mui Cheung, Hsiao‐Chin Hong, Ren‐Jun Hsu, Chen‐Yang Shen, Chia‐Wei Li, Weng‐Lang Yang, Yao‐Ming Chang, Shih‐Yu Chen, Chandan Guha, Shu‐Ping Wang   +20 more
wiley   +1 more source

349 A novel ‘off the shelf’ TCR-NK cell therapy platform for the treatment of solid tumours: development of optimised MAGE-A4 targeting TCR-NK cells for advancement into the clinic

Journal for ImmunoTherapy of Cancer, 2023
Ines Cardoso, Sylvie Pollmann, Luise U Weigand   +2 more
doaj   +1 more source

Advances and challenges in immunotherapy for intrahepatic cholangiocarcinoma based on the tumour immune microenvironment. [PDF]

Clin Transl Med
Chen M, Jin S, Zhou Y, Tong J, Zhao Y, Yang Q.   +5 more
europepmc   +1 more source

Coixenolide Enhances Antitumor Immunity of Cytotoxic CD8+ T Cells by Inhibiting S100A8/A9‐CD36 Axis in Obesity‐Associated Pancreatic Adenocarcinoma

Advanced Science, EarlyView.
Pancreatic adenocarcinoma (PAAD) remains highly lethal with limited treatment options. This study demonstrates that coixenolide, a bioactive compound from Coix lacryma‐jobi L. and a key component of the clinically approved Kanglaite injection, exhibits enhanced antitumor efficacy in high‐fat diet (HFD)‐induced obese mice bearing PAAD tumors compared to
Kaidi Chen, Rong Chen, Wei Li, Bin Song, Ruiying Zhang, Lewei Dai, Yuwei Qi, Ruqian Chen, Yifan Xu, Hangbin Li, Jingyi Huang, Fangping Wu, Jianan Peng, Xinyu Wang, Yang Xiong, Chaofeng Mu, Guilin Cheng, Zhaoshen Li, Shanming Ruan, Lei Huang, Mancang Gu   +20 more
wiley   +1 more source

Causal AI for cancer immunotherapy: a narrative framework review of target trial emulation, treatment-effect learning and clinical translation. [PDF]

Front Immunol
Zhao X, Liu Z, Yang J, Xie Q, Mao T, Zhou H, Wang H, Zheng P, Jiang K, Gao F.   +9 more
europepmc   +1 more source

The pathophysiology of sepsis and precision-medicine-based immunotherapy

Nature Immunology
E. Giamarellos-Bourboulis, A. Aschenbrenner, Michael Bauer, Christoph Bock, Thierry Calandra, I. Gat-Viks, E. Kyriazopoulou, M. Lupșe, G. Monneret, P. Pickkers, J. Schultze, T. van der Poll, F. L. van de Veerdonk, A. Vlaar, S. Weis, W. J. Wiersinga, M. Netea   +16 more
semanticscholar   +1 more source

Chemoproteomic Identification of AKT2 as a Paclitaxel‐Binding Protein via C─C Bond‐Linked Probe PTX‐4 in Paclitaxel‐Resistant Breast Cancer

Advanced Science, EarlyView.
ABSTRACT Breast cancer remains one of the most prevalent malignancies among women, and taxane‐based chemotherapies such as paclitaxel and docetaxel are central to standard treatment regimens. However, drug resistance in breast cancer limits therapeutic efficacy and contributes to recurrence and metastasis.
Kai Wang, Yuqing Yuan, Wei Shen, Xiuxiu Yang, Xiaokang Wu, Haihua Zhou, Yi Hu, Qing Zhu   +7 more
wiley   +1 more source